Minerva Neurosciences reported $83.1M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
Adma Biologics USD 575.86M 47.66M Sep/2026
ALKERMES USD 1.58B 57.83M Sep/2026
Alterity Therapeutics Limited AUD 37.91M 15.92M Dec/2025
AstraZeneca USD 31.45B 3.48B Sep/2026
BioCryst Pharmaceuticals USD 531.15M 46.47M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Cipla INR 250.61B 9.14B Sep/2026
Clal Biotechnology ILS 14.69M 1.95M Dec/2023
Compugen USD 129.41M 7.88M Jun/2026
CSL USD 11.85B 1000K Dec/2025
Eli Lilly USD 65.26B 591M Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
Grifols EUR 5.96B 316.31M Dec/2025
Halozyme Therapeutics USD 1.85B 913.71M Sep/2026
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Novavax USD 707.96M 63.14M Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sanofi EUR 33.21B 1.68B Sep/2026
Takeda JPY 3T 153.11B Sep/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025